Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 173   

Articles published

PFE 34.77 +0.45 (1.31%)
price chart
Pfizer Inc injects new generic medicines into its portfolio with US$17B ...
Pfizer Inc. agreed to buy Hospira Inc., the biggest provider of injectable drugs, in a transaction valued at about US$17 billion, adding an array of medicines and boosting its efforts to develop copies of biological drugs.
Analysts Weigh in on Pfizer Inc Following Acquisition Announcement of Hospira  ValueWalk
Pfizer agrees to buy Lake Forest's Hospira in $17B deal  Chicago Daily Herald
Pfizer Australia Lipitor Case Dismissed
MELBOURNE, Australia--The Federal Court of Australia on Wednesday dismissed a case against the local arm of Pfizer Inc. that alleged the drug company misused its market power to sell a popular cholesterol-lowering product.
JP Morgan Raises EPS Estimates For Pfizer (PFE) Stock
The sell-side research firm argued that the industry is now moving towards an era of new product launches and clinical data releases, with a focus on Pfizer Inc.'s (NYSE:PFE) Ibrance approval. Following this, Pfizer stock traded in the green today ...
Analyzing Ken Fisher's Holdings: Pfizer Inc. (PFE)
Pfizer, Inc. (PFE) is one of the major holdings of the firm. As of the last quarter, Fisher Asset Management was holding 31,196,415 shares of the company.
5 Things Pfizer, Inc.'s Management Wants You to Know
Times are challenging for Pfizer (NYSE: PFE ) , the largest pharmaceutical company in the world by revenue. In its latest quarterly report, Pfizer delivered a 3% decline in revenue to $13.12 billion as foreign currency translation headwinds and patent ...
Pfizer (PFE) Leading In Pre-Market Activity
Pfizer to cut jobs at Cambridge research center
Drug giant Pfizer Inc. said Tuesday that it plans to pare an unspecified number of jobs at its Cambridge research center, opened last June, as part a broader cutback across its research operations.
$4 Billion Opportunity: Pfizer inc. Snags Approval for Potential Blockbuster
One of the most anticipated drugs in Pfizer's (NYSE:PFE) pipeline just got a crucial FDA approval. The drug, (palbociclib, but trade-named Ibrance), treats one of the deadliest forms of breast cancer.
Pfizer's Breast Cancer Drug Approved Two Months Early by FDA  Bloomberg
FDA approves Pfizer drug to treat breast cancer in postmenopausal women  CTV News
Pfizer Inc. v. Mylan Pharms. Inc.
Case Name: Pfizer Inc. v. Mylan Pharms. Inc., Civ. No. 10-528-GMS, 2014 U.S. Dist. LEXIS 150283 (D. Del. Oct. 22, 2014) (Sleet, J.) (When a POSA would have to undertake significant guesswork to vary the parameters of prior-art compounds in order to ...
Pfizer in $5 billion accelerated buyback deal with Goldman, Sachs & Co
(Reuters) - Drugmaker Pfizer Inc (PFE.N) said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.
Pfizer Inc. (PFE) Strikes A $5 Billion Accelerated Share Repurchase Deal ...  Bidness ETC
Pfizer Commences $5 Billion Accelerated Share Repurchase  MarketWatch
Pfizer Inc. (PFE) Seeks Approval For Rare Lung Disease Medicine
The U.S. FDA has accepted Pfizer Inc. (NYSE:PFE)'s supplemental New Drug Application for Rapamune for priority review. The review is concerning the immunosuppressant's potential usage for a rare, fatal lung condition, Lymph-Angioleio-Myomatosis or ...
Pfizer Rapamune Under FDA Priority Review for Lung Disease
Pfizer Inc. (NYSE:PFE) Eagerly Preparing For Upcoming Events- Novavax, Inc ...  StreetWise Report